{"id":7464,"date":"2026-02-10T04:44:22","date_gmt":"2026-02-10T04:44:22","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/7464\/"},"modified":"2026-02-10T04:44:22","modified_gmt":"2026-02-10T04:44:22","slug":"pharmalittle-were-reading-about-novo-nordisk-suing-hims-hers-deals-by-lilly-and-takeda-and-more","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/7464\/","title":{"rendered":"Pharmalittle: We’re reading about Novo Nordisk suing Hims & Hers, deals by Lilly and Takeda, and more"},"content":{"rendered":"

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation. Our choice today is laced with traces of cocoa. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today and, of course, do keep in touch \u2026<\/p>\n

Novo Nordisk filed a lawsuit accusing Hims & Hers of infringing on a key patent for its widely sold Wegovy weight loss treatment, a new legal tactic by the drugmaker as it tries to thwart compounded versions of its big-selling medicine, STAT<\/a> writes. Specifically, Novo Nordisk claims the telehealth platform infringed on the patent for semaglutide, the active ingredient found in both the pill and injectable versions of Wegovy, as well as its Ozempic diabetes treatment. The patent expires in 2032 and covers any oral, injectable, or other drug containing semaglutide. The move comes after Hims & Hers last week announced plans\u00a0to sell a cheaper, compounded version of a new Wegovy obesity pill for $49 for the five first months, undercutting the $149 price charged by the drugmaker. The Food and Drug Administration approved the pill two months ago.<\/p>\n

Telehealth companies and compounding pharmacies that are continuing to make copycat versions of Novo Nordisk\u2019s highly popular obesity drug Wegovy \u201cshould be very, very much on notice,\u201d the drugmaker\u2019s general counsel told STAT<\/a>. The comments by Novo\u2019s John Kuckelman came shortly after the company filed a lawsuit\u00a0against Hims & Hers. The drugmaker alleged that the telehealth company is infringing on its patent for semaglutide, the active ingredient in Wegovy and its diabetes drug Ozempic. While Novo has filed dozens of lawsuits against these firms over claims like false advertising and deceptive trade practices, this is the first time Novo has filed a suit against Hims and the first time it\u2019s filed a patent suit, a much more aggressive tactic.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating…\n","protected":false},"author":2,"featured_media":7465,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[272,6268,359],"class_list":{"0":"post-7464","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-novo-nordisk","9":"tag-pharmalittle","10":"tag-stat"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/7464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=7464"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/7464\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/7465"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=7464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=7464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=7464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}